X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) topical gel is a prescription medicine which is now available in US for the topical treatment of acne vulgaris in patients 12 years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2024
Details:
Cabtreo (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide) Topical Gel which is indicated for the treatment of Acne Vulgaris in patients twelve years of age and older.
Lead Product(s): Clindamycin Phosphate,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Cabtreo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
IDP-126 (clindamycin 1.2%, adapalene 0.15%, benzoyl peroxide 3.1%) gel has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris by inhibiting bacterial protein synthesis.
Lead Product(s): Clindamycin Hydrochloride,Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: IDP-126
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
A combination of Adapalene (a retinoid) and Benzoyl Peroxide (an antibiotic and skin-peeling agent), the gel is used to decrease the number and severity of acne pimples. The drug will be manufactured at the group's topical facility at Ahmedabad, Zydus Lifesciences.
Lead Product(s): Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Adapalene/Benzoyl Peroxide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
IDP-126 Gel, an investigational drug, efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: randomized phase 2 and phase 3 studies of the first triple-combination drug.
Lead Product(s): Clindamycin Phosphate,Benzoyl Peroxide,Adapalene
Therapeutic Area: Dermatology Product Name: IDP-126
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bausch Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Adapalene and Benzoyl Peroxide combination is used to treat acne. It works by killing the bacteria that cause acne and by keeping the skin pores clean.
Lead Product(s): Adapalene,Benzoyl Peroxide
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
Details:
Adapalene Cream indicated for the topical treatment of acne vulgaris in Perrigo Topical Generic Rx Business.
Lead Product(s): Adapalene
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Altaris Capital Partners
Deal Size: $1,550.0 million Upfront Cash: $1,500.0 million
Deal Type: Divestment March 01, 2021
Details:
The meeting provided VYNE with clear direction on the Phase 3 clinical and pharmaceutical development plans for FCD105 and, should the clinical studies meet their objectives, the meeting provided further clarity on preparations required for the anticipated NDA.
Lead Product(s): Minocycline Hydrochloride,Adapalene
Therapeutic Area: Dermatology Product Name: FCD105
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
Company received important feedback on its trial design and program for its TRS01 Phase 3 program in uveitis, including feedback on its nonclinical and CMC plans supporting submission of a New Drug Application (NDA) in the U.S.
Lead Product(s): TRS01,Adapalene
Therapeutic Area: Ophthalmology Product Name: TRS01
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 17, 2020
Details:
FCD105 showed a highly statistically significant improvement compared to vehicle for the endpoints of Investigator’s Global Assessment treatment success and absolute change from baseline in mean inflammatory counts at Week 12.
Lead Product(s): Minocycline Hydrochloride,Adapalene
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
